http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2012157127-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 |
| filingDate | 2011-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2012157127-A |
| titleOfInvention | PHARMACEUTICAL COMPOSITION CONTAINING DAPOXETINE FOR ORAL ADMINISTRATION WITH SLOW DELIVERY |
| abstract | 1. A sustained release pharmaceutical composition for oral administration, comprising a rapid release phase and a sustained release phase, wherein said rapid release phase and a sustained release phase respectively comprise dapoxetine as an active ingredient; characterized in that dapoxetine contained in the indicated rapid release phase is eluted in an amount of 80 wt.% or more within 30 minutes, and dapoxetine contained in the indicated sustained release phase is eluted in an amount of less than 20 wt.% during the first 30 minutes 2. The pharmaceutical composition according to claim 1, characterized in that from 40 wt.% To 70 wt.% Of the total content of dapoxetine elutes during the first 30 minutes of elution. The pharmaceutical composition according to claim 1, characterized in that said rapid release phase and a sustained delayed release phase contain 20-80% by weight of dapoxetine from its total content, respectively. The pharmaceutical composition according to claim 3, characterized in that said rapid release phase and a sustained delayed release phase contain 40-60 wt.% Dapoxetine of its total content, respectively. The pharmaceutical composition according to claim 1, characterized in that said rapid release phase and a sustained delayed release phase contain 15-100 mg of dapoxetine, respectively. The pharmaceutical composition according to claim 5, characterized in that said rapid release phase and a sustained delayed release phase contain 30-60 mg of dapoxete� |
| priorityDate | 2010-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.